Cargando…
Prediction of Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors With a Panel of Autoantibodies: Protocol of a Multicenter, Prospective, Observational Cohort Study
Introduction: Immune checkpoint inhibitor (ICI) therapy is markedly improving the prognosis of patients with several types of cancer. On the other hand, the growth in the use of these drugs in oncology is associated with an increase in multiple immune-related adverse events (irAEs), whose optimal pr...
Autores principales: | Les, Iñigo, Pérez-Francisco, Inés, Cabero, María, Sánchez, Cristina, Hidalgo, María, Teijeira, Lucía, Arrazubi, Virginia, Domínguez, Severina, Anaut, Pilar, Eguiluz, Saioa, Elejalde, Iñaki, Herrera, Alberto, Martínez, Mireia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9198493/ https://www.ncbi.nlm.nih.gov/pubmed/35721217 http://dx.doi.org/10.3389/fphar.2022.894550 |
Ejemplares similares
-
Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events
por: Les, Iñigo, et al.
Publicado: (2023) -
Association of immune-related adverse events induced by nivolumab with a battery of autoantibodies
por: Les, Iñigo, et al.
Publicado: (2021) -
Prolonged disease control with local treatments in oligo-acquired resistance to immune-checkpoint inhibitors
por: Arasanz, Hugo, et al.
Publicado: (2023) -
Autoantibody profiles in patients with immune checkpoint inhibitor-induced neurological immune related adverse events
por: Müller-Jensen, Leonie, et al.
Publicado: (2023) -
Lower baseline autoantibody levels are associated with immune-related adverse events from immune checkpoint inhibition
por: Ghosh, Nilasha, et al.
Publicado: (2022)